My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharmather Hldgs Ltd (CSE:PHRM)

0.1950 -0.1750 (-47.30%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharmather Hldgs Ltd

< Previous 1 2 Next >
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update for Expected FDA Approval of Ketamine
Assigned FDA approval goal date of April 29, 2024, is still on track 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Provides Corporate Update
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
PharmaTher’s 4th FDA orphan drug designation for ketamine 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts
Via FinancialNewsMedia
Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027
Via FinancialNewsMedia
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.